Mornidine advertisements for postoperative recovery claimed "unusually low side effects".<ref name=AnnSurg/> However, contemporary comparative trials found that [[hypotension]] (low blood pressure) was a substantial concern when the drug was given at normal dosages for this indication; blood pressure reductions of up to 70&nbsp;mmHg were reported.<ref>{{cite journal |author=Blatchford E |title=Studies of anti-emetic drugs: A comparative study of cyclizine (Marzine), pipamazine (Mornidine), trimethobenzamide (Tigan), and hyoscine |journal=Canadian Journal of Anesthesia |volume=8 |issue=2 |pages=159–65 |date=March 1961 |doi=10.1007/BF03021345}}</ref> Reductions in dosage mitigated hypotension while maintaining antiemetic efficacy.

 


 
In his book ''The Creation of Psychopharmacology'', Irish psychiatrist [[David Healy (psychiatrist)|David Healy]] states that the failure of pipamazine to perform as a neuroleptic and its negative side effect profile helped Searle lose interest in the antipsychotic sector, and contributed to the company's refusal to market [[haloperidol]] in the United States.<ref>{{cite book |author=Healy D |chapter=Explorations in a new world |title=The creation of psychopharmacology |publisher=Harvard University Press |location=Cambridge |year=2002 |pages=123–4 |isbn=0-674-01599-1}}</ref>

 

